BACKGROUND/AIMS: Inhibition of hepatoma cells by cyclooxygenase (COX)-2-dependent and -independent mechanisms has been shown previously. Here, we examine the effect of Celecoxib, a COX-2-inhibitor and R-Etodolac, an enantiomer of the nonsteroidal anti-inflammatory drug Etodolac, which lacks COX-inhibitory activity, on the Wnt/beta-catenin pathway and human hepatoma cells. METHODS: Hep3B and HepG2 cell lines were treated with Celecoxib or R-Etodolac, and examined for viability, DNA synthesis, Wnt/beta-catenin pathway components, and downstream target gene expression. RESULTS: Celecoxib at high doses affected beta-catenin protein by inducing its degradation via GSK3beta and APC along with diminished tumor cell proliferation and survival. R-Etodolac at physiological doses caused decrease in total and activated beta-catenin protein secondary to decrease in its gene expression and post-translationally through GSK3beta activation. In addition, increased beta-catenin-E-cadherin was also observed at the membrane. An associated inhibition of beta-catenin-dependent Tcf reporter activity, decreased levels of downstream target gene products glutamine synthetase and cyclin-D1, and decreased proliferation and survival of hepatoma cells was evident. CONCLUSIONS: The antitumor effects of Celecoxib (at high concentrations) and R-Etodolac (at physiological doses) on HCC cells were accompanied by the down-regulation of beta-catenin demonstrating a useful therapeutic strategy in hepatocellular cancer.
BACKGROUND/AIMS: Inhibition of hepatoma cells by cyclooxygenase (COX)-2-dependent and -independent mechanisms has been shown previously. Here, we examine the effect of Celecoxib, a COX-2-inhibitor and R-Etodolac, an enantiomer of the nonsteroidal anti-inflammatory drug Etodolac, which lacks COX-inhibitory activity, on the Wnt/beta-catenin pathway and humanhepatoma cells. METHODS: Hep3B and HepG2 cell lines were treated with Celecoxib or R-Etodolac, and examined for viability, DNA synthesis, Wnt/beta-catenin pathway components, and downstream target gene expression. RESULTS:Celecoxib at high doses affected beta-catenin protein by inducing its degradation via GSK3beta and APC along with diminished tumor cell proliferation and survival. R-Etodolac at physiological doses caused decrease in total and activated beta-catenin protein secondary to decrease in its gene expression and post-translationally through GSK3beta activation. In addition, increased beta-catenin-E-cadherin was also observed at the membrane. An associated inhibition of beta-catenin-dependent Tcf reporter activity, decreased levels of downstream target gene products glutamine synthetase and cyclin-D1, and decreased proliferation and survival of hepatoma cells was evident. CONCLUSIONS: The antitumor effects of Celecoxib (at high concentrations) and R-Etodolac (at physiological doses) on HCC cells were accompanied by the down-regulation of beta-catenin demonstrating a useful therapeutic strategy in hepatocellular cancer.
Authors: Michael Hedvat; Anjali Jain; Dennis A Carson; Lorenzo M Leoni; Ganghua Huang; Stuart Holden; Desheng Lu; Maripat Corr; William Fox; David B Agus Journal: Cancer Cell Date: 2004-06 Impact factor: 31.743
Authors: Philippe Merle; Suzanne de la Monte; Miran Kim; Marc Herrmann; Shinji Tanaka; Annette Von Dem Bussche; Michael C Kew; Christian Trepo; Jack R Wands Journal: Gastroenterology Date: 2004-10 Impact factor: 22.682
Authors: Desheng Lu; Yandong Zhao; Rommel Tawatao; Howard B Cottam; Malini Sen; Lorenzo M Leoni; Thomas J Kipps; Maripat Corr; Dennis A Carson Journal: Proc Natl Acad Sci U S A Date: 2004-02-18 Impact factor: 11.205
Authors: Bernard J Komoroski; Shimin Zhang; Hongbo Cai; J Matthew Hutzler; Reginald Frye; Timothy S Tracy; Stephen C Strom; Thomas Lehmann; Catharina Y W Ang; Yan Yan Cui; Raman Venkataramanan Journal: Drug Metab Dispos Date: 2004-05 Impact factor: 3.922
Authors: Alfred S L Cheng; Henry L Y Chan; Ka F To; Wai K Leung; Ka K Chan; Choong T Liew; Joseph J Y Sung Journal: Int J Oncol Date: 2004-04 Impact factor: 5.650
Authors: Benjamin Cieply; Gang Zeng; Tracy Proverbs-Singh; David A Geller; Satdarshan P S Monga Journal: Hepatology Date: 2009-03 Impact factor: 17.425